

## Reduce the Incidence of Hypoglycemia and Hyperglycemia with the help of Glytec's eGMS®


Dips and spikes in patient blood glucose can prolong recovery and lead to dangerous complications. Unfortunately, many healthcare providers and hospital leaders accept high rates of hypo- and hyperglycemia as normal.

**They don't have to be. Poor glycemic management is typically driven by three factors:**

- Reliance on sliding-scale insulin therapy (which is outdated and ineffective<sup>1</sup>)
- Poor administration and avoidable errors<sup>2</sup>
- Lack of visibility into glycemic management performance<sup>3</sup>

By replacing outdated<sup>1</sup> and dangerous paper protocols<sup>1</sup>, creating workflows that decrease errors<sup>4</sup> and improve administration and providing data concerning glycemic management performance, **Glytec's FDA-cleared eGlycemic Management System can reliably and consistently reduce the incidence of hypo- and hyperglycemia in your healthcare system<sup>5</sup>.**


### How eGMS reduces the incidence of hypo-and hyperglycemia



# Hypo- and hyperglycemia aren't just bad for patients

Uncontrolled blood glucose is bad for patients, causing complications that can include confusion, seizures, coma and death.

But zoom out and you'll see that it's not just individual patients who pay for poor glyceic management. Both hypoglycemia and hyperglycemia are correlated with increases in length of stay, cost of care and readmissions.<sup>6</sup>



In addition, the Centers for Medicare & Medicaid Services (CMS) classifies patient death or serious disability associated with hypoglycemia as a “never event,”<sup>7</sup> and has proposed a measure for hypoglycemia which is currently going through the approval process<sup>8</sup>

**The bottom line:** glyceic management issues have ripple effects throughout the hospital, and resolving these issues can help stakeholders achieve broad quality, safety and financial goals.

# Real results from real hospitals




## Grady Hospital

Atlanta, GA | 640 beds

Comparing Glucomander IV to usual care in the treatment of 2,897 patients in their ICUs and step-down units, Grady Hospital saw reduced rates of severe hypoglycemia (BGs <40 mg/dL), moderate hypoglycemia (BGs <70 mg/dL) and hyperglycemia (BGs >250 mg/dL).<sup>9</sup>

### Rates of Hypoglycemia and Hyperglycemia




## AdventHealth Waterman

Tavares, FL | 269 beds

AdventHealth successfully used eGMS to reduce the number of preventable hypoglycemia-related adverse drug events.<sup>4</sup>

### Preventable Hypoglycemia-Related Adverse Drug Events



# Real results from real hospitals

## Nationwide retrospective analysis

180 U.S. hospitals

In a review of 116,917 patients who received IV insulin therapy guided by eGMS across a 2-year period, eGMS was found to result in a low incidence of hypoglycemia.<sup>5</sup>

## Average Incidence of Hypoglycemia and Hyperglycemia

	Compare these averages to your hospital's numbers to see just how much of a difference Glytec's eGMS could make.	
	Glytec's eGMS IV Insulin therapy	Your Hospital/Unit's IV Insulin Therapy
<b>Severe hypoglycemia</b> BGs <40 mg/dL	0.0160%	_____ %
<b>Moderate hypoglycemia</b> BGs <70 mg/dL	0.5295%	_____ %
<b>Hyperglycemia</b> BGs >250 mg/d	9.5%	_____ %

If your hospital system doesn't have hospital-wide, or unit-wide glycemic management metrics, how can you improve what you can't measure? Glytec's GlucoMetrics module allows providers at all levels and functional areas to review key blood glucose metrics and measure the progress of glycemic management initiatives.

## Let us answer your questions.

Contact Glytec to schedule a demo or discuss next steps.

Get in Touch

(864) 370-3297

glytecsystems.com

info@glytecsystems.com

## References

1. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes—2020. American Diabetes Association. Diabetes Care Jan 2020, 43 (Supplement 1) S193-S202; DOI: 10.2337/dc20-S015 Retrieved from [https://care.diabetesjournals.org/content/43/Supplement\\_1/S193](https://care.diabetesjournals.org/content/43/Supplement_1/S193).
2. Cousins D, Rosario C, Scarpello J. Insulin, hospitals and harm: a review of patient safety incidents reported to the National Patient Safety Agency. Clin Med (Lond). 2011 Feb;11(1):28-30. Retrieved from <https://doi.org/10.7861/clinmedicine.11-1-28>
3. Tanton D. Financial Implications of Poor Glycemic Management & Improvement Strategies for Optimal Outcomes. DTS Virtual Hospital Meeting, 2020.
4. Use of Technology Reduces Incidence of Hypoglycemia-Related Adverse Drug Events Among Patients Requiring Insulin Therapy While Hospitalized. Diabetes Technology Society (DTS) Virtual Poster Meeting, Jun 2020.
5. Reduction of Hypoglycemia Across 180 U.S. Hospitals Using eGlycemic Management System® for IV Insulin Therapy with ICU and non-ICU Patients. Diabetes Technology Society (DTS) Virtual Poster Meeting, Jun 2020.
6. Financial Implications of Poor Glycemic Management & Improvement Strategies for Optimal Outcomes. IHI Annual National Forum on Quality Improvement in Health Care, Dec 2018
7. Centers for Medicare & Medicaid Services. (2006). Eliminating Serious, Preventable, and Costly Medical Errors — Never Events. Retrieved from <https://www.cms.gov/newsroom/fact-sheets/eliminating-serious-preventable-and-costly-medical-errors-never-events>.
8. Glytec. (2020). What do you need to know about the Centers for Medicare & Medicaid Services (CMS) proposed hypoglycemia measure? Retrieved from <https://glytecsystems.com/resource/cms-measure-specification-hospital-harm-hypoglycemia/>.
9. Comparison of Hyperglycemia Management Protocols in the ICU: Standard Protocol versus eGlycemic Management System. American Diabetes Association Scientific Sessions, Jun 2019.

---

The eGlycemic Management System® is a modularized solution for glycemic management across the care continuum that includes Glucommander™. Glucommander™ is a prescription-only software medical device for glycemic management intended to evaluate current as well as cumulative patient blood glucose values coupled with patient information including age, weight and height, and, based on the aggregate of these measurement parameters, whether one or many, recommend an IV dosage of insulin, glucose or saline or a subcutaneous basal and bolus insulin dosing recommendation to adjust and maintain the blood glucose level towards a configurable physician- determined target range. Glucommander™ is indicated for use in adult and pediatric (ages 2-17 years) patients. The measurements and calculations generated are intended to be used by qualified and trained medical personnel in evaluating patient conditions in conjunction with clinical history, symptoms, and other diagnostic measurements, as well as the medical professional's clinical judgement. No medical decision should be based solely on the recommended guidance provided by this software program.

Glucommander™ is only available for use in the United States.

This content is only intended for use in the United States.

Customer service: (888) 458-2683